Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
The company posted revenue of €1,267 million, up 6% on a constant currency basis
The summit will bring together 1,200+ delegates, 100+ international faculty from 25 countries
The deal, backed by healthcare investor ARCHIMED, signals a major push to accelerate connected, patient-centered cardiac care worldwide
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
Health innovations are viewed more positively than food and agricultural technologies
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
Backed by ARCHIMED, the deal strengthens connected cardiac diagnostics with integrated Holter, ABPM, and telemedicine solutions
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Subscribe To Our Newsletter & Stay Updated
